Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Neukermans

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Emerging Infectious Diseases|November 20, 2004
Evaluating human papillomavirus vaccination programsAl V Taira, Christopher P Neukermans, Gillian D Sanders
The Lancet. Infectious Diseases|May 28, 2005
A synthesis of cost-utility analysis literature in infectious diseasePatricia W Stone, Bruce R Schackman, Christopher P Neukermans, et al.
Plos Medicine|May 31, 2007
Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in HaitiBruce R Schackman, Christopher P Neukermans, Sandy N Nerette Fontain, et al.
The New England Journal of Medicine|February 11, 2005
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapyGillian D Sanders, Ahmed M Bayoumi, Vandana Sundaram, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Emerging Infectious Diseases|November 20, 2004
Evaluating human papillomavirus vaccination programsAl V Taira, Christopher P Neukermans, Gillian D Sanders
The Lancet. Infectious Diseases|May 28, 2005
A synthesis of cost-utility analysis literature in infectious diseasePatricia W Stone, Bruce R Schackman, Christopher P Neukermans, et al.
Plos Medicine|May 31, 2007
Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in HaitiBruce R Schackman, Christopher P Neukermans, Sandy N Nerette Fontain, et al.
The New England Journal of Medicine|February 11, 2005
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapyGillian D Sanders, Ahmed M Bayoumi, Vandana Sundaram, et al.
Pageof 1